CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ab&B Bio Tech Co Ltd JS is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ab&B Bio Tech Co Ltd JS
No. 32
Xinglin Road, Medical High-Tech Zone
Phone: +86 52386819889p:+86 52386819889 TAIZHOU, JNG  China Ticker: 26272627
Business Summary
Ab&B Bio Tech Co Ltd JS is a China-based company primarily engaged in the research, development, manufacturing, and commercialization of vaccines. Its product pipeline includes two core products, the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with 11 other vaccine candidates. The Company primarily operates within the domestic market.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, General Manager YoucaiAn 58 4/1/2019 5/8/2017
Chief Financial Officer, Executive Director RunxiangLi 50 7/12/2021 1/1/2021
Chief Scientific Officer, Deputy General Manager ZeChen 60 9/16/2022 5/30/2022
10 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 393,442,600 (As of 3/31/2025)
Stock Exchange: HKG
Fax Number: +86 52386819869


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 22, 2025